NCT01122641View on ClinicalTrials.gov

The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

PHASE3CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

August 1, 2014

Study Completion Date

August 1, 2014

Conditions

Insulin ResistanceMicrovascular Disease

Interventions

DRUG

Vildagliptin

Vildagliptin 50mg bid

DRUG

Placebo

Matched tablets

Trial Locations (1)

EX2 5AX

Diabetes and Vascular Research Department, Exeter

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Royal Devon and Exeter NHS Foundation Trust

OTHER